Phendimetrazine

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

North America

USA: Bontril, Phendimetrazine.

Drug combinations

Chemistry

Phendimetrazine Tartrate: C~12~H~17~NO C~4~H~6~O~6~. Mw: 341.36. (1) Morpholine, 3,4-dimethyl-2-phenyl-, (2S-trans)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1); (2)(2S,3S)-3,4-Dimethyl-2-phenylmorpholine L-(+)-tartrate (1:1). CAS-50-58-8; CAS-634-03-7 (phendimetrazine).

Pharmacologic Category

Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous. (ATC-Code: A08AA).

Mechanism of action

Mechanism of action in reducing appetite appears to be secondary to CNS effects, including stimulation of hypothalamus to release norepinephrine.

Therapeutic use

Short-term (few weeks) adjunct in exogenous obesity.

Pregnancy and lactiation implications

Reproduction studies not conducted. Excretion in breast milk unknown.

Unlabeled use

Contraindications

Hypersensitivity or idiosyncrasy to phendimetrazine or other sympathomimetic amines or any component of the formulation. Advanced arteriosclerosis, symptomatic cardiovascular disease. Pulmonary hypertension. Moderate and severe hypertension. Hyperthyroidism. Glaucoma. Highly nervous or agitated states, history of drug abuse. Use with other CNS stimulants. During or within 14 days following MAOI therapy.

Warnings and precautions

Amphetamines may impair ability to engage in potentially hazardous activities. A rare, frequently fatal disease of the lungs, primary pulmonary hypertension, found to occur with increased frequency in patients receiving some anorexigens. Use of some anorexigens associated with development of valvular heart disease. Avoid stimulants in known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems which could increase risk of sudden death that these conditions alone carry. Use with caution in diabetes mellitus (antidiabetic agent requirements may be altered), in hypertension and other cardiovascular conditions which might be exacerbated by increases in blood pressure or heart rate, in history of seizure disorders, and in Tourette’s syndrome (stimulants may unmask tics). Not recommended for use in patients who have used other anorectic agents within the past year. Prolonged use may lead to dependency.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart